NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

According to the American Kidney Fund, kidney disease is growing at an alarming rate. It currently affects more than one in ...

If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

Obesity comes with several health issues including heart problems, hypertension and kidney disease. Here’s how managing ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

FSGS damages the kidney’s filtering units ... higher rates of diabetes and hypertension (the two leading causes of kidney disease), and structural barriers to healthcare access.

Travere Therapeutics (TVTX) has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking priority review ...

The success of a kidney transplant largely depends on patient awareness, consistent care, and adherence to medical advice ...